ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies

被引：5
|
作者：
Poei, Darin [1 ]
Ali, Sana [2 ]
Ye, Shirley [1 ]
Hsu, Robert [2 ,3 ]
机构：
[1] Univ Southern Calif, Dept Internal Med, Los Angeles, CA 90033 USA
[2] Univ Southern Calif, Norris Comprehens Canc Ctr, Div Med Oncol, Los Angeles, CA 90033 USA
[3] Univ Southern Calif, Norris Comprehens Canc Ctr, Dept Med, Div Med Oncol, 1441 Eastlake Ave, Los Angeles, CA 90033 USA
来源：
CANCER DRUG RESISTANCE | 2024年 / 7卷
关键词：
NSCLC; ALK TKI; acquired resistance; alectinib; crizotinib; lorlatinib; ceritinib; brigatinib; CELL LUNG-CANCER; LYMPHOMA KINASE ALK; GENERATION SEQUENCING REVEALS; PREFERRED 1ST-LINE OPTION; FACTOR RECEPTOR EGFR; OPEN-LABEL; TYROSINE KINASE; PHASE-II; CRIZOTINIB RESISTANCE; ACQUIRED-RESISTANCE;
D O I：
10.20517/cdr.2024.25
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Anaplastic lymphoma kinase (ALK) gene rearrangements have been identified as potent oncogenic drivers in several malignancies, including non-small cell lung cancer (NSCLC). The discovery of ALK inhibition using a tyrosine kinase inhibitor (TKI) has dramatically improved the outcomes of patients with ALK-mutated NSCLC. However, the emergence of intrinsic and acquired resistance inevitably occurs with ALK TKI use. This review describes the molecular mechanisms of ALK TKI resistance and discusses management strategies to overcome therapeutic resistance.
引用
收藏
页数：22
相关论文
共 50 条
  • [1] Molecular resistance mechanisms of ALK inhibitors and implications for therapeutic management of ALK-rearranged lung cancer patients
    Niu, Xiaomin
    Perdomo, Sandra
    Blackhall, Fiona
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S239 - S245
  • [2] Resistance mechanisms to ALK inhibitors
    Katayama, Ryohei
    Yanagitani, Noriko
    Koike, Sumie
    Sakashita, Takuya
    Kitazono, Satoru
    Nishio, Makoto
    Okuno, Yasushi
    Engelman, Jeffrey A.
    Shaw, Alice T.
    Fujita, Naoya
    CANCER RESEARCH, 2015, 75
  • [3] Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer
    Katayama, Ryohei
    PHARMACOLOGY & THERAPEUTICS, 2017, 177 : 1 - 8
  • [4] Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
    Alissa J. Cooper
    Lecia V. Sequist
    Jessica J. Lin
    Nature Reviews Clinical Oncology, 2022, 19 : 499 - 514
  • [5] Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
    Cooper, Alissa J.
    Sequist, Lecia, V
    Lin, Jessica J.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (08) : 499 - 514
  • [6] The mechanisms of resistance to second- and third-generation ALK inhibitors and strategies to overcome such resistance
    Haratake, Naoki
    Toyokawa, Gouji
    Seto, Takashi
    Tagawa, Tetsuzo
    Okamoto, Tasuro
    Yamazaki, Koji
    Takeo, Sadanori
    Mori, Masaki
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (09) : 975 - 988
  • [7] Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data
    Toyokawa, Gouji
    Seto, Takashi
    ONCOLOGY RESEARCH AND TREATMENT, 2015, 38 (06) : 291 - 298
  • [8] Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
    Isozaki, Hideko
    Takigawa, Nagio
    Kiura, Katsuyuki
    CANCERS, 2015, 7 (02) : 763 - 783
  • [9] Predication of lorlatinib resistance mechanisms and therapeutic strategies to overcome the resistance in ALK rearranged non-small cell lung cancer
    Okada, Koutaroh
    Araki, Mitsugu
    Oh-hara, Tomoko
    Nishio, Makoto
    Okuno, Yasushi
    Fujita, Naoya
    Katayama, Ryohei
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [10] Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies
    Wong, Rachel S. J.
    Ong, Rebecca J. M.
    Lim, Joline S. J.
    CANCER DRUG RESISTANCE, 2023, 6 (06) : 768 - 787
12345